Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Large Japanese Pharmas Seek To Fill Domestic Gap For Obesity Drugs

This article was originally published in PharmAsia News

Executive Summary

Several of the larger Japanese drug makers are focusing on developing drugs aimed at treating obesity in a segment of the domestic population for which few medicines exist. Eisai has applied for approval of a drug by U.S.-based Abbott Laboratories that causes brain neurotransmitters to fool the body to believe it is full. Shionogi and Takeda Pharmaceutical also have anti-obesity drugs in their pipelines, Shionogi is set to begin human clinical trials this summer and Takeda is watching Phase III trials for a drug it licensed from a U.K. bioventure. (Click here for more - a subscription may be required

You may also be interested in...



AZ and GSK Dip Into Diagnostics To Support COVID-19 UK Tests

The pharma giants are joining forces to help the UK reach its ambitious target of testing 100,000 people a day for coronavirus by the end of April.

Angelini Sets Up In Germany As It Unveils ThermaCare Plans

Angelini is looking to take its recently-acquired ThermaCare brand to the next level by establishing a direct base in Germany to market the product and through a new distribution deal with Norway's Navamedic.

Becton Dickinson, BioMedomics Collaborate On Rapid Serology COVID-19 Test

BD and BioMedomics have released a new rapid point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19.

UsernamePublicRestriction

Register

SC071854

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel